Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study

Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.

Related Content:

Hematologic OncologyRapid Readouts

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML